anticyp7b1 Search Results


anti-cyp7b1  (MyBiosource Biotechnology)
90
MyBiosource Biotechnology anti-cyp7b1
Comparative analysis of hepatic levels of obeticholic acid (OCA) target gene expression and bile acid composition in the responder and non-responder groups after treatment. ( A ) Comparative analysis of the hepatic levels of OCA target gene expression levels in the vehicle and OCA groups. Data are presented as mean ± standard error of mean. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (Unpaired t-test and one-way analysis of variance). The expression levels of genes involved in the ( B ) classical and ( C ) alternative pathways of bile acid synthesis. ( D ) Comparative analysis of hepatic Star mRNA levels. Data are mean ± standard error of mean. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (one-way analysis of variance). ( E ) Immunoblotting and ( F ) quantification of hepatic protein levels of Cyp7a1, Cyp8b1, <t>Cyp7b1,</t> and Cyp39a1 (vehicle (n = 8), non-responder (n = 11) and responder (n = 7)). Data are presented as mean ± standard error of mean. ** p < 0.01 (one-way analysis of variance). ( G , H , and I ) Analysis of bile acid composition in the mouse liver tissue. Data are presented as mean ± standard error of mean. ** p < 0.01 (Mann-Whitney U test). ( J ) Correlation between Cyp39a1 and Cyp7b1 mRNA levels and muricholic acids (MCAs). Correlation was analyzed using the nonparametric Spearman’s correlation coefficient. Differences were considered significant at p < 0.05
Anti Cyp7b1, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anticyp7b1/anti+cyp7b1/pmc10463927-179-7-9
Average 90 stars, based on 1 article reviews
anti-cyp7b1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-cyp7b1 (q127) antibody  (Boster Bio)
N/A
Boster Bio Anti-CYP7B1 (Q127) Antibody catalog # A03545. Tested in IHC applications. This antibody reacts with Human,Mouse,Rat.
   Buy from Supplier
anti-cyp7b1 (aa 1-100) polyclonal antibody  (Creative BioMart)
N/A
CYP7B1 (cytochrome P450, family 7, subfamily B, polypeptide 1) is a protein-coding gene. Diseases associated with CYP7B1 include bile acid synthesis defect, congenital, 3, and spastic paraplegia 5a, and among its related super-pathways are Synthesis
   Buy from Supplier
anti-cyp7b1  (Atlas Antibodies)
N/A
cytochrome P450, family 7, subfamily B, polypeptide 1, Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence
   Buy from Supplier
anti-cyp7b1 antibody picoband  (Boster Bio)
N/A
Boster Bio Anti-CYP7B1 Antibody Picoband® catalog # A03545-3. Tested in WB, IHC, Flow Cytometry, ELISA applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior
   Buy from Supplier
goat anti-cyp7b1  (everest biotech)
N/A
   Buy from Supplier
anti-cyp7b1 mouse monoclonal antibody  (Boster Bio)
N/A
Boster Bio CYP7B1 mouse monoclonal antibody,clone OTI1G7. Catalog# M03545. Tested in IHC, WB. This antibody reacts with Human.
   Buy from Supplier
anti-cyp7b1 (aa 443-506) polyclonal antibody  (Creative BioMart)
N/A
CYP7B1 (cytochrome P450, family 7, subfamily B, polypeptide 1) is a protein-coding gene. Diseases associated with CYP7B1 include bile acid synthesis defect, congenital, 3, and spastic paraplegia 5a, and among its related super-pathways are Synthesis
   Buy from Supplier
anti-cyp7b1 monoclonal antibody, clone 3c22  (Creative BioMart)
N/A
Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.http://www.creative-diagnostics.com/CYP7B1-antibody-60120-144.htm
   Buy from Supplier
anti-cyp7b1 (full length) polyclonal antibody  (Creative BioMart)
N/A
CYP7B1 (cytochrome P450, family 7, subfamily B, polypeptide 1) is a protein-coding gene. Diseases associated with CYP7B1 include bile acid synthesis defect, congenital, 3, and spastic paraplegia 5a, and among its related super-pathways are Synthesis
   Buy from Supplier
anti-cyp7b1 (aa 259-289) polyclonal antibody  (Creative BioMart)
N/A
CYP7B1 (cytochrome P450, family 7, subfamily B, polypeptide 1) is a protein-coding gene. Diseases associated with CYP7B1 include bile acid synthesis defect, congenital, 3, and spastic paraplegia 5a, and among its related super-pathways are Synthesis
   Buy from Supplier
anti-cyp7b1 antibody  (St Johns Laboratory)
N/A
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This
   Buy from Supplier

Image Search Results


Comparative analysis of hepatic levels of obeticholic acid (OCA) target gene expression and bile acid composition in the responder and non-responder groups after treatment. ( A ) Comparative analysis of the hepatic levels of OCA target gene expression levels in the vehicle and OCA groups. Data are presented as mean ± standard error of mean. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (Unpaired t-test and one-way analysis of variance). The expression levels of genes involved in the ( B ) classical and ( C ) alternative pathways of bile acid synthesis. ( D ) Comparative analysis of hepatic Star mRNA levels. Data are mean ± standard error of mean. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (one-way analysis of variance). ( E ) Immunoblotting and ( F ) quantification of hepatic protein levels of Cyp7a1, Cyp8b1, Cyp7b1, and Cyp39a1 (vehicle (n = 8), non-responder (n = 11) and responder (n = 7)). Data are presented as mean ± standard error of mean. ** p < 0.01 (one-way analysis of variance). ( G , H , and I ) Analysis of bile acid composition in the mouse liver tissue. Data are presented as mean ± standard error of mean. ** p < 0.01 (Mann-Whitney U test). ( J ) Correlation between Cyp39a1 and Cyp7b1 mRNA levels and muricholic acids (MCAs). Correlation was analyzed using the nonparametric Spearman’s correlation coefficient. Differences were considered significant at p < 0.05

Journal: Biology Direct

Article Title: Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

doi: 10.1186/s13062-023-00407-4

Figure Lengend Snippet: Comparative analysis of hepatic levels of obeticholic acid (OCA) target gene expression and bile acid composition in the responder and non-responder groups after treatment. ( A ) Comparative analysis of the hepatic levels of OCA target gene expression levels in the vehicle and OCA groups. Data are presented as mean ± standard error of mean. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (Unpaired t-test and one-way analysis of variance). The expression levels of genes involved in the ( B ) classical and ( C ) alternative pathways of bile acid synthesis. ( D ) Comparative analysis of hepatic Star mRNA levels. Data are mean ± standard error of mean. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (one-way analysis of variance). ( E ) Immunoblotting and ( F ) quantification of hepatic protein levels of Cyp7a1, Cyp8b1, Cyp7b1, and Cyp39a1 (vehicle (n = 8), non-responder (n = 11) and responder (n = 7)). Data are presented as mean ± standard error of mean. ** p < 0.01 (one-way analysis of variance). ( G , H , and I ) Analysis of bile acid composition in the mouse liver tissue. Data are presented as mean ± standard error of mean. ** p < 0.01 (Mann-Whitney U test). ( J ) Correlation between Cyp39a1 and Cyp7b1 mRNA levels and muricholic acids (MCAs). Correlation was analyzed using the nonparametric Spearman’s correlation coefficient. Differences were considered significant at p < 0.05

Article Snippet: Additionally, the liver sections were stained with anti-Cyp7b1 (MBS768409, MyBioSource, CA, USA) and anti-Cyp8b1 antibodies (PA5-37088, Thermo Fisher Scientific, MA, USA) overnight at 4 °C.

Techniques: Expressing, Western Blot, MANN-WHITNEY

Responder classification based on the Cyp7b1/Cyp8b1 ratio. ( A ) The expression of bile acid-associated cytochrome P450 genes in the responder group relative to that in the OCA-treated mouse liver tissue. ( B ) Responder and non-responder classification according to the Cyp7b1/Cyp8b1 ratio. Data are presented as mean ± standard error of mean. * p < 0.05 (Unpaired t-test). ( C ) Ratio of responder mice among the OCA-treated mice overexpressing cytochrome P450 genes and the response rate according to the Cyp7b1/Cyp8b1 ratio

Journal: Biology Direct

Article Title: Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

doi: 10.1186/s13062-023-00407-4

Figure Lengend Snippet: Responder classification based on the Cyp7b1/Cyp8b1 ratio. ( A ) The expression of bile acid-associated cytochrome P450 genes in the responder group relative to that in the OCA-treated mouse liver tissue. ( B ) Responder and non-responder classification according to the Cyp7b1/Cyp8b1 ratio. Data are presented as mean ± standard error of mean. * p < 0.05 (Unpaired t-test). ( C ) Ratio of responder mice among the OCA-treated mice overexpressing cytochrome P450 genes and the response rate according to the Cyp7b1/Cyp8b1 ratio

Article Snippet: Additionally, the liver sections were stained with anti-Cyp7b1 (MBS768409, MyBioSource, CA, USA) and anti-Cyp8b1 antibodies (PA5-37088, Thermo Fisher Scientific, MA, USA) overnight at 4 °C.

Techniques: Expressing

Effect of OCA on the LX-2 cells transfected with short-interfering RNA (siRNA) against CYP7B1 (si-CYP7B1) and glucose on the expression levels of cytochrome P450 family genes related to bile acid synthesis. ( A ) Wound healing assay using TGFβ1 and OCA in scramble and si-CYP7B1-transfected LX-2 cells. ( B ) A wound was introduced in the monolayer of scramble and si-CYP7B1-transfected cells. Wound healing was measured after 24 h. ( C ) Evaluation of fibrosis-related marker proteins. Comparative analysis of CYP7A1 , CYP8B1 , and CYP7B1 mRNA levels according to ( D ) glucose concentrations in HepG2 cells. ( E ) RORA and NR1H3 mRNA levels according to glucose concentration. Comparative analysis of CYP7A1 , CYP8B1 , and CYP7B1 mRNA levels according to ( F ) insulin concentrations in HepG2 cells. Data are shown in bar diagrams as mean ± standard error of mean from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (one-way analysis of variance). Scale bars, 200 μm

Journal: Biology Direct

Article Title: Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

doi: 10.1186/s13062-023-00407-4

Figure Lengend Snippet: Effect of OCA on the LX-2 cells transfected with short-interfering RNA (siRNA) against CYP7B1 (si-CYP7B1) and glucose on the expression levels of cytochrome P450 family genes related to bile acid synthesis. ( A ) Wound healing assay using TGFβ1 and OCA in scramble and si-CYP7B1-transfected LX-2 cells. ( B ) A wound was introduced in the monolayer of scramble and si-CYP7B1-transfected cells. Wound healing was measured after 24 h. ( C ) Evaluation of fibrosis-related marker proteins. Comparative analysis of CYP7A1 , CYP8B1 , and CYP7B1 mRNA levels according to ( D ) glucose concentrations in HepG2 cells. ( E ) RORA and NR1H3 mRNA levels according to glucose concentration. Comparative analysis of CYP7A1 , CYP8B1 , and CYP7B1 mRNA levels according to ( F ) insulin concentrations in HepG2 cells. Data are shown in bar diagrams as mean ± standard error of mean from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (one-way analysis of variance). Scale bars, 200 μm

Article Snippet: Additionally, the liver sections were stained with anti-Cyp7b1 (MBS768409, MyBioSource, CA, USA) and anti-Cyp8b1 antibodies (PA5-37088, Thermo Fisher Scientific, MA, USA) overnight at 4 °C.

Techniques: Transfection, Small Interfering RNA, Expressing, Wound Healing Assay, Marker, Concentration Assay